首页> 外文期刊>Cancer Medicine >Prognostic value of early radiological response to first‐line platinum‐containing chemotherapy in patients with metastatic nasopharyngeal carcinoma
【24h】

Prognostic value of early radiological response to first‐line platinum‐containing chemotherapy in patients with metastatic nasopharyngeal carcinoma

机译:转移性鼻咽癌患者含一线铂含铂化疗的早期放射响应预后价值

获取原文
           

摘要

Background To explore the prognostic value of early radiological response (ERR) to first‐line platinum‐containing chemotherapy in patients with metastatic nasopharyngeal carcinoma (mNPC), as well as its correlation with the best radiological response (BRR). Patients and methods A total of 756 mNPC patients with measurable lesions who received first‐line platinum‐containing chemotherapy were enrolled in this study. ERR was defined as complete or partial response after 6?weeks of chemotherapy according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. We performed survival analyses according to the radiological response after repeated chemotherapy. Log‐rank test and Cox regression were used to analyze the survival data. Results About 470 patients achieved ERR and 78 patients achieved subsequent response (objective response after repeated chemotherapy). ERR patients had better OS (P??.001, median OS: 34.3 vs 22.2?months) and PFS (P??.001, median PFS: 10.2 vs 7.4?months) than non‐ERR ones. ERR (OS: HR?=?0.591, 95% CI, 0.495‐0.705, P??.001, PFS: HR?=?0.586, 95% CI, 0.500‐0.686, P??.001) was independently prolonged survival compared with non‐ERR ones. Besides, ERR was significantly correlated with the BRR (Kappa: 0.73; Pearson: 0.74, P??.001), and had significantly longer OS and PFS than patients with subsequent response, respectively. Conclusion ERR is an independent prognostic factor in determining survival in mNPC patients received first‐line platinum‐containing chemotherapy, which may be a more sensitive predictor to assess overall efficacy of systemic treatment than BRR in mNPC. Prospective validation studies are needed.
机译:背景技术探讨早期放射反应(ERR)的预后价值(ERR)在转移性鼻咽癌患者(MNPC)患者中含有一线铂化化疗,以及与最佳放射响应(BRR)的相关性。患者和方法共有756例MNPC患者患有可衡量的含含含铂化疗的可测量病灶的患者均参与本研究。根据实体肿瘤的响应评估标准(Recist)1.1,err被定义为6次化疗后的完整或部分反应。我们根据反复化疗后的放射性反应进行存活分析。日志秩测试和COX回归用于分析生存数据。结果470名患者达到了ERR和78名患者的后续反应(反复化疗后客观反应)。 ERR患者具有更好的操作系统(P?<〜001,中位数OS:34.3与22.2?月)和PFS(P?

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号